Vivos Therapeutics Registers 3.96M Shares for Resale by Armistice Capital, Signaling Potential 29% Dilution Amidst Financial Distress

summarizeSummary

Vivos Therapeutics filed an S-3/A to register 3.96 million shares for resale by Armistice Capital, LLC, representing a potential 29% dilution, with the company receiving no direct proceeds from these sales, against a backdrop of a 'going concern' warning and Nasdaq non-compliance.

check_boxKey Events

• Significant Resale Registration

  Vivos Therapeutics filed an S-3/A to register 3,964,712 shares of common stock for resale by Armistice Capital, LLC, stemming from a January 20, 2026 warrant inducement private placement.

• Substantial Potential Dilution

  These shares represent a potential dilution of 29.12% to the company's currently outstanding common stock.

• No Direct Proceeds from Sales

  The company will not receive any proceeds from the sale of these shares by the selling stockholder. Potential proceeds from warrant exercise (up to $8.28M) are unlikely given the current stock price of $0.84 is below the $2.09 exercise price.

• Context of Financial Distress

  This registration occurs amidst the company's recent disclosure of a 'going concern' warning in its 2025 10-K and a formal Nasdaq non-compliance notice received on April 22, 2026.

auto_awesomeAnalysis

This S-3/A filing enables Armistice Capital, LLC, a significant institutional investor, to potentially sell 3.96 million shares of Vivos Therapeutics common stock, representing a substantial 29.12% of current outstanding shares. While the company will not receive direct proceeds from these sales, it could receive up to $8.28 million if the warrants are exercised for cash. However, with the current stock price of $0.84 significantly below the $2.09 exercise price, a cash exercise is improbable. This registration creates a considerable overhang on the stock, adding to investor uncertainty, especially as the company recently disclosed a 'going concern' warning and received a Nasdaq non-compliance notice.